Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of Its Linea(TM) IVT Platform
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of Its Linea(TM) IVT Platform
Patent covers the Composition of the Company's Proprietary Linea RNAP, a Core Technology Empowering the Linea IVT Platform
專利涵蓋公司專有的Linea RNAP組合,這是一種核心技術,支持了Linea IVT平台
Patent Application Also Currently Pending in Key International Markets
專利申請目前也在關鍵國際市場中等待中
STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled "Compositions and Methods for RNA Synthesis."
紐約州, STONY BROOK / ACCESSWIRE / 2024年6月5日 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (應用DNA或“公司”),一個PCR基因DNA技術領域的領導者,今天宣佈,它收到了美國專利商標局(USPTO)對18/302,247號專利申請的“RNA合成組成物和方法”的通知批准。
The resulting patent will cover the composition of the Company's chemically modified RNA polymerase enzyme branded Linea RNAP, with expected patent protection into 2041. Linea RNAP is a core component of the Company's Linea IVT platform that empowers mRNA manufacturers to produce better mRNA faster via a simplified mRNA production workflow with reduced or eliminated double-stranded RNA (dsRNA) contamination. Applied DNA acquired the technology underlying the Linea RNAP via its acquisition of Spindle Bio, Inc. in July 2023.
由此衍生的專利涵蓋公司的化學修飾RNA聚合酶酶品牌Linea RNAP組成,預計專利保護將持續到2041年。Linea RNAP是公司Linea IVT平台的核心組成部分,該平台使mRNA製造商能夠通過簡化的mRNA生產工作流程更快地生產更好的mRNA,並減少或消除雙鏈RNA(dsRNA)的污染。應用DNA通過其於2023年7月收購Spindle Bio,Inc獲得了Linea RNAP基礎技術。
"This patent allowance, coupled with the upcoming initiation of our GMP capabilities, demonstrates our commitment to supplying GMP-grade critical starting materials for the manufacture of mRNA," said Dr. James A. Hayward, president and CEO of Applied DNA. "With approximately 450 mRNA therapies under development globally, and with a large majority of these therapies in the preclinical stage, we believe we can build significant market share via our differentiated Linea IVT platform and its numerous advantages over conventional mRNA production workflows."
“這項專利批准,再加上我們即將啓動的GMP能力,表明我們致力於爲mRNA製造提供GMP級關鍵起始物質,”應用DNA總裁兼首席執行官詹姆斯·A·海沃德博士表示,“全球有約450種mRNA療法正在研發中,其中絕大多數療法處於臨床前階段,我們相信我們可以通過我們區別於傳統mRNA生產工作流程的Linea IVT平台和其衆多優勢來建立重要的市場份額。”
About the Linea DNA and Linea IVT Platforms
關於Linea DNA和Linea IVT平台
The Linea DNA platform is an entirely cell-free DNA production platform founded on Applied DNA's long-standing expertise in the large-scale enzymatic production of DNA. Capable of producing DNA in quantities ranging from milligrams to grams, the Linea DNA platform can produce high-fidelity DNA constructs ranging from 100bp to 20kb in size. The DNA produced via the Linea DNA platform is free of the adventitious DNA sequences found in other sources of DNA, is rapidly scalable, and provides for simple chemical modification of DNA constructs.
Linea DNA平台是一個完全脫細胞DNA生產平台,該平台建立在應用DNA對大規模DNA酶法生產的長期專業技術基礎上。能夠從毫克到克的量級產生高保真的DNA構建物,其長度從100bp到20kb不等。通過Linea DNA平台生產的DNA不含其他來源中發現的偶發DNA序列,可快速擴展,並提供對DNA構建物的簡單化學修飾。
The Linea IVT platform combines DNA IVT templates manufacturing via the Linea DNA platform with a proprietary Linea RNAP to enable mRNA and sa-mRNA manufacturers to produce what Applied DNA believes to be better mRNA faster, with advantages over conventional mRNA production, including: 1) the elimination of plasmid DNA as a starting material; 2) the prevention or reduction of double-stranded DNA (dsRNA) contamination; and 3) simplified mRNA production workflows.
Linea IVT平台結合了通過Linea DNA平台製造的DNA IVT模板生產和專有的Linea RNAP,使mRNA和sa-mRNA製造商能夠快速生產更好的mRNA,具有優於傳統mRNA生產的優勢,包括:1)消除質粒DNA作爲起始物; 2) 預防或減少雙鏈DNA(dsRNA)污染;和3)簡化mRNA生產工作流程。
About Applied DNA Sciences
關於Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and, through our recent acquisition of Spindle Biotech, Inc. ("Spindle"), the development and sale of a proprietary RNA polymerase ("RNAP") for use in the production of mRNA therapeutics; (ii) the detection of DNA and RNA in molecular diagnostics and genetic testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
應用DNA科學是一家正在開發生產和檢測脫氧核糖核酸(“DNA”)技術的生物技術公司。我們利用聚合酶鏈反應(“PCR”)來實現DNA的生產和檢測,從三個主要業務市場開展業務:(i)產生合成DNA的酶法制造,用於核酸爲基礎的治療產品及多肽,並且通過我們最近對Spindle Biotech公司的收購提供了用於生產mRNA治療藥物的專有RNA聚合酶(“RNAP”)的開發和銷售;(ii)檢測分子診斷和遺傳測試服務中的DNA和RNA;和(iii)供應鏈安全服務的製造和檢測DNA。
Visit adnas.com for more information. Follow us on X and LinkedIn. Join our mailing list.
請訪問adnas.com了解更多信息。關注我們的X和領英。加入我們的郵件列表。
Forward-Looking Statements
前瞻性聲明
The statements made by Applied DNA in this press release may be "forward-looking" in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA's future plans, projections, strategies, and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, the availability of sufficient financial and other resources to meet business objectives and operational requirements the unknown future demand for its biotherapeutics products and services, the unknown amount of revenues and profits that will result from its Linea IVT and or Linea DNA platforms, the development and utilization of, and challenges to, our intellectual property, the fact that there has never been a commercial drug product utilizing PCR-produced DNA technology and/or the Linea IVT platform approved for therapeutic use, and various other factors detailed from time to time in Applied DNA's SEC reports and filings, including its Annual Report on Form 10-K, as amended, filed on December 7, 2023 and Quarterly Report on Form 10-Q filed on February 8, 2024, and May 10, 2024, and other reports it files with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Applied DNA在本新聞稿中做出的言論可能是“前瞻性”的,在1933年證券法第27A節、1934年證券交易法第21E節和1995年私人證券訴訟改革法中,以此描述了Applied DNA的未來計劃、規劃、戰略和期望,並基於假設涉及多個風險和不確定性,其中許多都超出了Applied DNA的控制範圍。由於歷史淨虧損、有限的財務資源、可用的足夠財務和其他資源以滿足業務目標和運營要求、其生物治療產品和服務未來需求未知、Linea IVT平台和/或Linea DNA平台產生的未知收入和利潤數量、我們的知識產權開發和利用以及挑戰,PCR生產的DNA技術和/或Linea IVT平台的商業藥品產品從未獲得批准用於治療用途,以及來自時間到時間的各種其他因素,實際結果可能與預測有所不同。應用DNA的SEC報告和備案(包括於2023年12月7日修訂的10-K表格的年度報告和於2024年2月8日、5月10日以及在其他時間提交的其他報告)中不時詳細說明這些風險和不確定性以及其他因素,這些報告可以在www.sec.gov獲得。應用DNA無需公開更新任何前瞻性語句,以反映此後發生的任何新信息、事件或情況,除非法律另有規定。
Contacts:
聯繫人:
Applied DNA Sciences
Applied DNA Sciences
Investor Relations contact: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com
投資者關係聯繫人:Sanjay M. Hurry,917-733-5573,sanjay.hurry@adnas.com
Program contact: Clay Shorrock, 631-912-6454, clay.shorrock@adnas.com
計劃聯繫人:Clay Shorrock,631-912-6454,clay.shorrock@adnas.com
Web:
網站:
Twitter: @APDN
Twitter:@APDN
SOURCE: Applied DNA Sciences, Inc.
SOURCE: Applied DNA Sciences, Inc.